Market Access: Hainan Boao Hope City Fast-Tracks Approval for 5 Advanced Fertility Drugs Ahead of Mainland Rollout

Written By camellia chen

【Abstract】: The Hainan Boao Lecheng International Medical Tourism Pilot Zone has announced the accelerated approval of five new imported ovarian stimulation and luteal support drugs widely used in Europe but not yet NMPA-cleared for mainland China.

Business Insight: This reinforces Hainan’s status as the "Internal Offshore" hub for medical tourism. For international pharmaceutical companies, Boao remains the critical "bridgehead" to enter the Chinese market early and gather Real-World Data (RWD) to accelerate full national registration. Domestic clinics should view Hainan not just as a competitor, but as a referral partner for patients needing access to cutting-edge pharmacotherapy.

【Keywords】: #HainanBoao #PharmaMarketAccess #ChinaIVFRegulation

【Source】: Hainan Daily / Lecheng Pilot Zone Administration (Feb 5, 2026)

camellia chen
Previous

Clinical Shift: Demand for "Mild Stimulation" IVF Protocols Rises 45% in Tier-1 Cities
Next

Next-Gen Screening: First Multi-Center Pilot for Embryo "Whole Genome Sequencing" Launches in Beijing